or Try an Advanced Search...

    Technical Analysis for CLYM - Climb Bio, Inc.

    Grade Last Price % Change Price Change
    F 3.08 -5.23% -0.17
    CLYM closed down 5.23 percent on Wednesday, November 20, 2024, on 22 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical CLYM trend table...
    Date Alert Name Type % Chg
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    Slingshot Bearish Bearish Swing Setup -5.23%
    MACD Bullish Signal Line Cross Bullish -5.23%
    Wide Bands Range Expansion -5.23%
    Oversold Stochastic Weakness -5.23%
    MACD Bearish Signal Line Cross Bearish 0.65%
    NR7 Range Contraction 0.65%
    Wide Bands Range Expansion 0.65%
    Oversold Stochastic Weakness 0.65%
    Older End-of-Day Signals for CLYM ...

       Recent Intraday Alerts

    Alert Time
    Down 2 % about 20 hours ago
    Down 1% about 20 hours ago
    Up 2% about 20 hours ago
    Up 1% about 20 hours ago
    Rose Above Previous Day's High 2 days ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    CLYM Chart by TradingView
    Basic chart:

    Profile

    Climb Bio, Inc. operates as a clinical-stage biotechnology company. It develops therapeutics for patients with immune-mediated diseases. Its lead product candidate, budoprutug, is an anti-CD19 antibody designed for a broad range of B-cell mediated diseases. The company was founded by Andrew D. Levin and Valerie Morisset on October 18, 2018 and is headquartered in Wilmington, DE.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Molecular Biology Gene Therapy Immune Mediated Diseases Bioethics

    Is CLYM a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 12 Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights
    Nov 11 Climb Bio names Douglas Williams as chair
    Nov 11 Climb Bio Appoints Douglas E. Williams, Ph.D., as Chair of the Board
    Oct 31 Climb Bio to Present at Upcoming Investor Conferences
    Oct 11 Climb Bio Announces Abstract Selected for Presentation at the American Society of Nephrology Kidney Week 2024
    Oct 2 Eliem Therapeutics Changes Name to Climb Bio
    Oct 2 Eliem Therapeutics Announces Rebranding and Corporate Name Change to Climb Bio, Inc.
    Sep 28 Private equity firms who have a significant stake must be disappointed along with institutions after Eliem Therapeutics, Inc.'s (NASDAQ:ELYM) market cap dropped by US$231m
    Sep 23 Eliem Therapeutics: Recent Strategic Pipeline Restructuring
    Aug 14 Eliem Therapeutics GAAP EPS of -$1.81
    See more CLYM news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 11.55
    52 Week Low 2.35
    Average Volume 606,046
    200-Day Moving Average 5.62
    50-Day Moving Average 5.10
    20-Day Moving Average 3.69
    10-Day Moving Average 3.43
    Average True Range 0.36
    RSI (14) 31.03
    ADX 42.02
    +DI 12.71
    -DI 27.81
    Chandelier Exit (Long, 3 ATRs) 3.78
    Chandelier Exit (Short, 3 ATRs) 4.08
    Upper Bollinger Bands 4.53
    Lower Bollinger Band 2.84
    Percent B (%b) 0.14
    BandWidth 45.76
    MACD Line -0.52
    MACD Signal Line -0.53
    MACD Histogram 0.0112
    Fundamentals Value
    Market Cap 84.92 Million
    Num Shares 27.6 Million
    EPS -1.46
    Price-to-Earnings (P/E) Ratio -2.11
    Price-to-Sales 0.00
    Price-to-Book 0.66
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 3.51
    Resistance 3 (R3) 3.55 3.44 3.44
    Resistance 2 (R2) 3.44 3.33 3.42 3.41
    Resistance 1 (R1) 3.26 3.26 3.21 3.22 3.39
    Pivot Point 3.16 3.16 3.13 3.14 3.16
    Support 1 (S1) 2.98 3.05 2.92 2.94 2.77
    Support 2 (S2) 2.87 2.98 2.85 2.75
    Support 3 (S3) 2.69 2.87 2.72
    Support 4 (S4) 2.65